Skip to main content
. 2015 Mar 26;125(19):3024–3031. doi: 10.1182/blood-2015-01-623991

Figure 3.

Figure 3

Disease-specific relapse risks. Cumulative incidences by competing-risk analysis of relapse in intermediate-risk aggressive NHL (n = 84) (A) and relapse in intermediate-risk AML (n = 64) (B) based on refined DRI grouping.